All In Biotech

Drug Trial Radar · NCT06260709

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Feb 20, 2024

Primary completion

Feb 29, 2028

Study completion Feb 9, 2030

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for approximately 6 years or until NNC6019-0001 is commercially or otherwise available to the participant, whichever comes first.

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions

  • NNC6019-0001Drug

    Intravenous NNC6019-0001 every 4 weeks added to the standard of care up to 300 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events (TEAEs)Time frame: From baseline (week 0) to up to 6 years

Locations

38 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Cedars-Sinai Medical Center_Los Angeles

    Los Angeles, California

  • Stanford Hlth Cre-Boswell Clin

    Stanford, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • NW Univ-Bluhm Cardiovasc Inst

    Chicago, Illinois

  • NW Univ-Bluhm Cardiovasc Inst

    Evanston, Illinois

  • Univ of MD Schl of Med

    Baltimore, Maryland

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • University of Calgary_Cardiology

    Calgary, Alberta, Canada

  • Ctr for Cardiovascular Innovation

    Vancouver, British Columbia, Canada

  • II. interni klinika VFN - Kardiologie a angiologie

    Prague, Czechia

  • Ap-Hp-Hopital Henri Mondor

    Créteil, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1

    Toulouse, France

  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil

    Toulouse, France

  • UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie

    Heidelberg, Germany

  • Universitätsklinik Heidelberg Innere Medizin III Kardiologie, Angiologie, Pneumologie

    Heidelberg, Germany

  • LMU Klinikum München Klinik und Poliklinik 1

    München, Germany

  • Uniklinik Münster, Klinik für Kardiologie I

    Münster, Germany

  • Universitätsklinikum Münster - Klinik für Kardiologie I

    Münster, Germany

  • Universitatsklinikum Wurzburg AöR

    Würzburg, Germany

  • Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz

    Würzburg, Germany

  • Fondazione CNR-Regione Toscana Gabriele Monasterio

    Pisa, Pi, Italy

  • Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare

    Pisa, Pi, Italy

  • Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo

    Pavia, PV, Italy

  • Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology

    Fukuoka, Japan

  • Hiroshima University hospital, Cardiovascular Medicine

    Hiroshima, Japan

  • Hiroshima University hospital_Cardiovascular Medicine

    Hiroshima, Japan

  • Kumamoto University Hospital, Cardiovascular Medicine

    Kumamoto-shi, Kumamoto, Japan

  • Shinshu University Hospital, Department of Neurology

    Nagano, Japan

  • Nagasaki University Hospital, Cardiovascular Medicine

    Nagasaki, Japan

  • Okayama University Hospital_Cardiovascular Medicine

    Okayama, Japan

  • UMC Groningen

    Groningen, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Hospital da Senhora da Oliveira - Guimarães

    Guimarães, Portugal

  • ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães

    Guimarães, Portugal

  • ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real

    Vila Real, Portugal

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.